HKEX: 1952
Next Day Disclosure Return
Earlier from Everest Medicines
- Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults
- Everest Medicines Announces Interim Results for First Half of 2026
- Everest Medicines to Announce 2026 Interim Results and Host Online Investor Call on August 19, 2026
- Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib